GNT Biotech & Medicals
Privately held: no public share price · Taiwan
Assets
(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
5Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | HDACSmall molecule | Non-Small Cell Lung CancerBreast CancerDiffuse Large B-Cell LymphomaColorectal CancerNon-Hodgkin Lymphoma HR+/HER2- Metastatic Breast Cancer, Peripheral T-Cell Lymphoma |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2028 (1)
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
14 July 2026Topline resultHBI-8000 (chidamide)Phase 3 HBI-8000-303 (NCT04674683) of HBI-8000 plus nivolumab in advanced melanoma met its primary endpoint
HUYABIO International, LLC. · Source ↗
Financial reports
No financial reports recorded.